The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 14 February 2025, approved efanesoctocog alfa (brand name Altuvoct) to be used to treat and prevent bleeding in patients aged 2 years and above with severe or moderate haemophilia A.
Efanesoctocog alfa, the active substance, is a replacement factor VIII protein. This protein is naturally found in the body and is necessary for the blood to form clots and stop bleeding…
